Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.

Autor: Roche S; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., Gaule P; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., Winrow D; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., Mukherjee N; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., O'Neill F; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., Conlon NT; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., Meiller J; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., Collins DM; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., Canonici A; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., Fawsi MI; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., Estepa-Fernández A; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., Madden SF; Data Science Centre, Royal College of Surgeons in Ireland, Dublin, Ireland., Crown J; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland.; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland., O'Donovan N; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland., Eustace AJ; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland.

Publikováno v: PloS one [PLoS One] 2023 Mar 15; Vol. 18 (3), pp. e0282512. Date of Electronic Publication: 2023 Mar 15 (Print Publication: 2023).